NVCR News and Press, NovoCure Limited From 12/10/20

Novocure ([[NVCR]] +5.0%) has enrolled the first patient in its Phase 3 TRIDENT trial, in newly diagnosed glioblastoma testing the potential survival benefit of initiating Optune concurrent with radiation therapy. Optune is a noninvasive, antimitotic cancer treatment that delivers Tumor ...

TRIDENT will test the potential survival benefit of initiating Optune concurrent with radiation therapy in patients with newly diagnosed glioblastoma Preclinical studies demonstrate that Tumor Treating Fields increase sensitivity to radiation therapy and inhibit DNA damage rep...

The oncology market covers every area of cancer care, from diagnosis to treatment, and is one of the biggest sectors in the life science space. Cancer is the second leading cause of death worldwide, after cardiovascular diseases. Biotechnology and pharmaceutical companie...

Novocure (NASDAQ: NVCR) announced today that Novocure’s Executive Chairman William Doyle and Chief Science Officer Dr. Uri Weinberg will participate in the 3 rd Annual Evercore ISI 2020 Virtual HealthCONx Conference on December 1 through December 2, 2020. Mr. Doyle and Dr. We...

Shares of Novocure (NASDAQ: NVCR) were sinking 9.2% as of 3:30 p.m. on Tuesday. The oncology therapy company didn't announce any news, so why did the stock fall on a day when the overall market soared? The most likely reason is that some investors decided to lock in profits after No...

Two new breakout stocks for Week 48 with better than 10% short-term upside potential. This past week, two out of four stocks gained over 10% led by peak gains in VERI +48.6% and FLGT +22.4% with avg portfolio gains of +12%. The streak of weekly picks gaining over 10% in less than ...

Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 85 percent of presentations prepared by external authors Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields will be featured at the Society for Neuro-...

Palm Beach, FL – November 17, 2020 – With the increasing prevalence of brain cancer, rising aging population, and growing incidences of cancer via chemical exposure, the demand of diagnosis and treatment of brain tumors is steadily increasing. The diagnosis, treatments, therap...

Novocuore has disruptive technologies in cancer treatments. The company has enormous room for growth if management delivers. Revenue growth is accelerating. The stock is not too expensive considering the company's growth prospects. The nature of the business is intrinsical...

Novocure (NVCR) has received the CE Mark for the NovoTTF-100L system, for the commercialization of the device as a first-line treatment in combination with Eli Lilly's Alimta (pemetrexed) and platinum-based chemotherapy for malignant pleural mesothelioma ((MPM)), in the Europea...